Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Protagen to Support Pfizer Clinical Drug Development

Published: Tuesday, December 03, 2013
Last Updated: Tuesday, December 03, 2013
Bookmark and Share
Protagen have signed a collaboration agreement with Pfizer Inc.

Under the collaboration, Protagen will use its proprietary SeroTag® process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.

Protagen CEO Stefan Müllner comments, “The current agreement shows that the SeroTag® process of Protagen is relevant technology to explore novel biomarkers in support of clinical development in inflammatory and autoimmune diseases. We look forward to a productive and collaborative relationship with Pfizer's R&D team.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protagen AG Achieves ISO 13485 Certification
The ISO 13485 certification covers the development, production and distribution of in-vitro diagnostics (IVD) for autoimmune diseases.
Wednesday, June 24, 2015
Protagen AG Appoints Bernhard Kirschbaum as New Board Member
Announcement follows recent strategic partnership between Protagen and Qiagen.
Thursday, January 08, 2015
Protagen Successfully Closes New Financing Round
QIAGEN N.V. joins existing investors.
Tuesday, December 16, 2014
Protagen AG and QIAGEN Collaborate
Protagen and QIAGEN partner to offer pharmaceutical companies an innovative companion diagnostic development platform for autoimmune disorders.
Monday, November 17, 2014
Protagen AG Sells Service Business
Protagen AG, Dortmund, divested its 100% subsidiary Protagen Protein Services GmbH (PPS), to Zukunftsfond Heilbronn.
Tuesday, July 02, 2013
Protagen counts on Kairos Expertise in Biobank- Management
Both companies plan long term partnership in which Protagen will profit from the administration and documentation of thousands of patient samples. Protagen will actively present and demonstrate the expertise of Kairos to the market.
Friday, March 30, 2012
Protagen Expands Cooperation with Bayer HealthCare
New collaboration project for the clinical validation of diagnostic biomarkers in Endometriosis.
Thursday, December 08, 2011
Protagen at the European Antibody Congress 2010
Company experts will present the characterization of biotherapeutics with protein microarrays and the latest developments of GMP-compliant protein analysis.
Wednesday, November 03, 2010
Protagen AG and MicroDiscovery GmbH Cooperate in Biomarker Development
The cooperation is aimed to identify and validate biomarkers for medically relevant diseases.
Monday, October 25, 2010
Protagen Raises € 10.0 Million for Diagnostic Developments
Funds will be utilized for the targeted expansion of the business unit Diagnostics and the clinical validation of proprietary diagnostic marker proteins.
Thursday, September 09, 2010
Key Patent of Protagen Granted in Japan
The patent claims broadly a method for identifying and selecting clones relating to the basic UNIclone® technology.
Friday, August 13, 2010
Evaluation of UNIarray® for Infectious Disease Diagnostics
Protagen and Mikrogen close their collaboration agreement for the identification of typical autoantibody signatures in infectious diseases.
Thursday, July 08, 2010
Protagen Deepens Cooperation with Bayer Schering Pharma
Both the companies announce the closing of a cooperation contract for discovery of novel biomarkers in Endometriosis.
Thursday, June 10, 2010
UNIchip Protein Biochips from Protagen Identify Significant Off-target binding for TNF-alpha Inhibitors
Findings could explain side effects seen with these biological drugs for treating rheumatic diseases.
Thursday, April 03, 2008
UNIchip protein biochips from Protagen identify significant off-target binding for TNF-alpha inhibitors
Tumor Necrosis Factor-a inhibitors used to treat rheumatic diseases may bind to a significant number of proteins other than their main target, according to the results of an in vitro study published in Analytical and Bioanalytical Chemistry.
Monday, March 31, 2008
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!